Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Welcome to Slider's Dugout -- Ignore unavailable to you. Want to Upgrade?

To: Jamey who wrote (14329)	1/12/2009 10:08:46 AM
From: Jamey	Respond to of 50645

Marketwatch MITI Micromet- MITI Bid: 4.22 Ask: 4.28 Last: 4.30 ($): 0.28 Vol: 32,745 Bayer Schering Pharma Signs Antibody Licensing AgreementLast update: 1/12/2009 8:09:10 AMEdited Press Release FRANKFURT (Dow Jones)--Bayer AG's (BAY.XE) pharmaceuticals business Bayer Schering Pharma AG said Monday it has acquired an exclusive option for a collaboration and licensing agreement with Micromet, Inc., a biopharmaceutical company developing antibodies for the treatment of cancer, inflammation and autoimmune diseases. Bayer Schering Pharma will pay Micromet a EUR4.5 million fee to secure a one-year option on a specific BiTE antibody. Exercising this option prior to Jan. 5, 2010 through an additional payment would trigger a joint collaboration on the development of the BiTE antibody against a solid tumor target through the completion of Phase I clinical trials, at which point Bayer Schering Pharma would assume full control of the further development and commercialization of the antibody. Micromet would be eligible for an option exercise fee and milestone payments of up to EUR290 million in total and up to double-digit royalties based on tiered net sales of the product. "Oncology is one of our core growth areas and biologicals are a key focus of our strategy. We are excited about Micromet's BiTE antibody technology and believe BiTE antibodies represent a novel and promising approach to cancer therapy," said Andreas Busch, Member of the Board of Management of Bayer Schering Pharma AG responsible for Global Drug Discovery. "We are very pleased with Bayer's interest in this preclinical BiTE antibody program and their financial commitment to secure exclusive access for the next 12 months. This deal represents further validation of BiTE antibody technology by a major oncology company," said Christian Itin, Micromet's Chief Executive Officer.